Savara, Inc.

4.3400-0.07 (-1.59%)

Oct 29, 4:00:00 PM EDT · NasdaqGS · SVRA · USD

Upcoming Earnings

Report date

≈ Nov 14, 2025 (in 15 days)

Key Stats

Market Cap

750.11M

P/E (TTM)

Basic EPS (TTM)

-0.51

Dividend Yield

Recent Filings

8-K

9/2/25Sep 2, 2025

10-Q

8/13/25Aug 13, 2025

8-K

6/6/25Jun 6, 2025

8-K

5/27/25May 27, 2025

10-Q

5/13/25May 13, 2025

About

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

CEO

Mr. Matthew Pauls J.D., M.B.A.

IPO

4/28/2017

Website

https://www.savarapharma.com

Employees

Sector

Healthcare

Industry

Biotechnology